Testing a new injectable form of medication for children with inflammatory bowel disease

This trial is testing vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. The study will first give participants intravenous infusions of the medication over 6 weeks, and then switch those who improve to self-injections given at home every 2 or 4 weeks (depending on body weight) for 5 months. Researchers want to make sure this injectable form works safely and effectively in young patients.

Many children with inflammatory bowel disease struggle to manage their condition with current treatments. This medication has helped adult patients, but doctors need to test whether the injectable version works well and is safe in children, and determine the best dosing schedule based on a child's weight.